If you typed CIDEPRO into a search box, you are probably building a CRO shortlist. This article uses only what CIDEPRO publishes (cideprocolombia.org/cidepro) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What CIDEPRO publishes
CIDEPRO is a Colombian organization offering preclinical and clinical research services to the pharmaceutical, biotechnology and medical device industries, with a tilt toward tropical and public-health product development. We found no named device study on its site.
CIDEPRO vs bioaccess®
| Dimension | CIDEPRO | bioaccess® |
|---|---|---|
| Core focus | Colombia preclinical + clinical services | First-in-human and early feasibility studies for medical devices |
| Geography | See provider site | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you need preclinical work in Colombia, or a public-health product program, CIDEPRO's mix is the right shape.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including CIDEPRO, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the CIDEPRO public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply